Phase 2 N=643 HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis
End Stage Renal Disease · Chronic Pain · Opioid Dependence
Primary: Pain Interference — 6.26; 6.45; 5.09; 5.75 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Lymphoma, Mantle-Cell
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B — 1; 0; 0; 2 Participants
Phase 2 N=10 Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device
Ocular Surface Disease
Primary: Ocular Surface Disease Index (OSDI) Score Change (1 Month Post Treatment Initiation) — -3.83 score on a scale
Phase 2 N=41 Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)
COVID-19 (Coronavirus Disease 2019) · Hypoxia
Primary: Measuring the Change in Inflammation — 23.23; 34.82 mg/L — p=0.01
Phase 2 N=123 Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
Ovarian Neoplasms
Primary: Efficacy: Progression Free Survival (PFS) — 3.1; 5.6; 3.8 months — p=0.265
Phase 2 N=23 Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women
Polycystic Ovary Syndrome (PCOS)
Primary: Lipid Content of PCOS Subcutaneous (SC) Abdominal Adipocytes Matured in Vitro. — 2.0; 5.6; 1.37; 3.8 fluorescence units/cell number — p=0.004
Phase 2 N=109 Neuroinflammation and Modulating Factors in Depression and HIV
Depression · HIV
Primary: Change in Patient Health Questionnaire (PHQ)-9 — 5; 7 units on a scale
Phase 2 N=20 Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate Using RECIST v1.1 to Nivolumab and Ipilimumab When Administered in Combination to Patients With Pre-treated Advanced NSCLC Who Have Experienced…
Phase 2 N=50 Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
Classical Hodgkin Lymphoma
Primary: PART A: Number of Participants Who Complete of 2 Cycles of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) — 30 Participants
Phase 2 N=71 A Study of TAK-861 in Participants With Narcolepsy Type 2
Narcolepsy Type 2
Primary: Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8 — 2.14; 1.90; 4.54 minutes — p==0.989
Phase 2 N=112 A Study of TAK-861 in Participants With Narcolepsy Type 1
Narcolepsy Type 1
Primary: Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8 — -1.16; 12.49; 23.50; 25.42 minutes — p==0.001
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 2 N=25 HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
Duchenne Muscular Dystrophy · Cardiomyopathy
Primary: Number of Participants Experiencing Any of the Adjudicated Events — 0; 0; 0; 0 Participants
Phase 2 N=13 Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
Hypertrophic Cardiomyopathy
Primary: Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events — 13; 5 Participants
Phase 2 N=117 OZONE_EXO: Comparative Analysis of Protocols for Dental Exactions in Patients at Risk of MRONJ: Case-control Study
MEDICATION RELATED OSTEONECROSIS OF THE JAW
Primary: Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Inflammatory Phase — 2; 2.49 score on a scale